ReviewJournal of nephrology2017
Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.
Review in Journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis.Immunity, inflammation and disease · 2026Pooled it
- Which commercial Chinese polyherbal preparations combined with ACEI/ARB is effective and safe for IgA nephropathy? A systematic review and network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.International urology and nephrology · 2023Pooled it
- Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies.Renal failure · 2022Pooled it
- Red blood cell casts on kidney biopsy and progression of IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2026Article
- Analysis of changes in glomerular lesions in children diagnosed with IgA nephropathy following immunosuppressive therapy.BMC nephrology · 2026Article
- Prognosis and predictive factors in pediatric IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2026Article
- Machine learning-based unsupervised phenotypic clustering analysis of patients with IgA nephropathy: Distinct therapeutic responses of different groups.Chinese medical journal · 2026Article
- Dapagliflozin reduces proteinuria in IgA nephropathy patients receiving immunosuppressive therapy.Renal failure · 2025Article
- Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study.Journal of nephrology · 2025Article
- Modern Biomarkers in IgA Nephropathy and Their Potential in Paediatric Research.Journal of clinical medicine · 2025Review
- Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.Canadian journal of kidney health and disease · 2025Review
- The impact of metabolic component count on IgA nephropathy prognosis.Scientific reports · 2024Article
- Childhood-onset IgA nephropathy: is long-term recovery possible?Pediatric nephrology (Berlin, Germany) · 2024Article
- The incidence and prevalence of IgA nephropathy in Europe.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Review
- TNF-α-mediated podocyte injury via the apoptotic death receptor pathway in a mouse model of IgA nephropathy.Renal failure · 2022Article
- The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.International urology and nephrology · 2022Article
- Management of IgA Nephropathy in Pediatric Patients.Children (Basel, Switzerland) · 2022Article
- Implications of Sphingolipid Metabolites in Kidney Diseases.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of risk factors conditioning the progression of immunoglobulin (Ig)A nephropathy (IgAN) is needed due to the variability of the outcome of this renal disease, which ranges from remission or indolent course to progressive slow loss of renal function or rapidly evolving chronic renal failure. Based on the supposed individual risk of progression, the therapy is modulated from renin-angiotensin inhibitors to corticosteroids, alone or associated with other powerful but potentially harmful immunosuppressors. Over the last 20 years, several studies have produced great advances in the field of biomarkers for detecting risk factors that play a role in the progression of IgAN. This review will focus on the clinical and histological risk factors which have been detected and validated by the majority of the studies and which may presently be considered of value for prognostication of outcome in patients with IgAN, driving the individual treatment choice.
Indexed as
Identifiers
27815919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.